Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Stock analysts at Alliance Global Partners reduced their Q1 2025 EPS estimates for Curaleaf in a research note issued on Tuesday, March 4th. Alliance Global Partners analyst A. Grey now anticipates that the company will post earnings per share of ($0.08) for the quarter, down from their previous forecast of ($0.07). The consensus estimate for Curaleaf's current full-year earnings is ($0.25) per share. Alliance Global Partners also issued estimates for Curaleaf's Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.30) EPS and FY2026 earnings at ($0.23) EPS.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.09. The firm had revenue of $331.05 million for the quarter, compared to the consensus estimate of $331.87 million. Curaleaf had a negative net margin of 14.82% and a negative return on equity of 13.67%.
Separately, Roth Capital upgraded Curaleaf to a "strong-buy" rating in a research report on Sunday, November 10th.
Get Our Latest Stock Report on Curaleaf
Curaleaf Trading Down 2.0 %
CURLF stock traded down $0.02 during midday trading on Thursday, reaching $0.99. 985,502 shares of the company traded hands, compared to its average volume of 748,980. The firm has a market capitalization of $654.02 million, a price-to-earnings ratio of -3.41 and a beta of 0.57. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.51 and a current ratio of 1.11. The business has a 50 day moving average of $1.41 and a 200-day moving average of $2.13. Curaleaf has a 52-week low of $0.88 and a 52-week high of $6.40.
About Curaleaf
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Featured Articles
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
